Delirium is a condition of acute disturbance in attention and awareness along with disturbances in cognition. It is a symptom of deranged homeostasis and an early sign of infection or hypoxia. The occurrence of COVID-19 brought a catastrophic reduction in delirium monitoring, prevention, and patient care due to several organizational issues like lack of personnel, increased use of benzodiazepines and restricted family visitation.
For the future development of an ideal intensive care unit (ICU) it is important to make the patients free from delirium. As delirium is associated with worse ICU-related outcomes and long-term cognitive impairment in critical illnesses.
Screening for delirium requires limited time and effort. Completing good sedation practices by novel ICU design and connectivity will facilitate non-pharmacological sedation, anxiolysis and comfort which can further be supplemented by balanced pharmacological interventions when necessary. Improvements in the ICU sound, light control, floor planning, and room arrangement can also facilitate a healing environment which would eventually minimize stressors and aid delirium prevention and management.
The fundamental prerequisite to realize the delirium-free ICU, is an awake non-sedated, pain-free comfortable patient whose management follows the A to F (A–F) bundle. Moreover, gaining (G) insight into patient needs, delivering holistic care with a ‘home-like’ (H) environment, and redefining ICU architectural design (I).
The most important thing is to obtain a delirium-free world. It requires optimization of design of ICU, environmental factors, management, time spent with the patient and family by the criticare teams during their routine ICU care.
Read more such content on Hidoc Dr | Medical Learning App for Doctors
1.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
2.
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer
3.
Germline Profiling May Improve Risk Stratification in t-MNs
4.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
5.
Scientists call into question safety of potential new anticancer treatment
1.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
2.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
3.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
4.
Ferroptosis Signaling in Tumor Progression and Therapeutic Resistance
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Clinical Insights in Hematology
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation